Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis

Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by multisystemic manifestations including asthma. Mepolizumab (300 mg/4 weeks) has recently been approved for EGPA. However, real-life data are scarce and report experiences with high doses of mepolizumab intravenousl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Allergy Asthma Immunol Res
Autors principals: Vultaggio, Alessandra, Nencini, Francesca, Bormioli, Susanna, Vivarelli, Emanuele, Dies, Laura, Rossi, Oliviero, Parronchi, Paola, Maggi, Enrico, Matucci, Andrea
Format: Artigo
Idioma:Inglês
Publicat: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2020
Matèries:
Brief Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7346991/
https://ncbi.nlm.nih.gov/pubmed/32638567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4168/aair.2020.12.5.885
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars